ReviewNature reviews. Clinical oncology2018
Exogenous reproductive hormone use in breast cancer survivors and previvors.
Review in Nature reviews. Clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Contraception use and changes in young women with newly diagnosed breast cancer.Fertility and sterility · 2025Trial
- The roles of anti-Müllerian hormone in breast cancer.Endocrine-related cancer · 2023Review
- Review
- What Is Known about Breast Cancer in Young Women?Cancers · 2023Review
- Contraception in breast cancer survivors from the FEERIC case-control study (performed on behalf of the Seintinelles research network).Breast (Edinburgh, Scotland) · 2023Article
- Identification of the six-hormone secretion-related gene signature as a prognostic biomarker for colon adenocarcinoma.Cancer biomarkers : section A of Disease markers · 2023Article
- Contraceptive Use in Premenopausal Women With Early Breast Cancer.JAMA network open · 2022Article
- Management of genitourinary syndrome of menopause in breast cancer survivors: An update.World journal of clinical oncology · 2022Review
- Chest Feminization in Male-to-Female Transgender Patients: A Review of Options.Transgender health · 2021Review
- Genomic Analysis Uncovers Immune Microenvironment Characteristics and Drug Sensitivity of Ferroptosis in Breast Cancer Brain Metastasis.Frontiers in genetics · 2021Article
- A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer.Breast cancer (Dove Medical Press) · 2021Review
- Role of Curcumin in Regulating Long Noncoding RNA Expression in Cancer.Advances in experimental medicine and biology · 2021Article
- Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review.Endocrine · 2020Review
- Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considerable controversy exists regarding the safety of elective exogenous hormonal exposure among breast cancer survivors and women at high risk of developing the disease (referred to herein as 'previvors'). We performed a qualitative analysis focused on four areas of potential exogenous exposure to hormones among previvors and survivors: hormonal contraception; systemic hormone-replacement therapy (HRT); localized HRT; and hormonal manipulation for fertility preservation or enhancement. Herein, we discuss the available data and present clinical recommendations regarding the safety of hormonal exposure for both previvors and survivors. We found these data to be hampered by small cohort sizes, heterogeneous patient populations, and limited study designs, highlighting a great need to conduct further research with the aim of enabling better-informed patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.